Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA

References

• Global Initiative for Chronic Obstructive Lung Disease [homepage on the Internet]Global Strategy for the Diagnosis, Management and Prevention of COPD2018 Available from: http://www.goldcopd.orgAccessed February 5, 2018
   Google Scholar
• GBD 2015 Chronic Respiratory Disease CollaboratorsGlobal, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015Lancet Respir Med20175969170628822787
   PubMed Web of Science ®Google Scholar
• CurrieGPLipworthBJInhaled treatment for chronic obstructive pulmonary disease: what’s new and how does it fit?QJM2016109850551226559079
   PubMed Web of Science ®Google Scholar
• AstraZeneca Pharmaceuticals LPBevespi Aerosphere™ [prescribing information]2017 Available from: http://www.azpicentral.com/bevespi/bevespi_pi.pdfAccessed February 5, 2018
   Google Scholar
• MartinezFJRabeKFFergusonGTEfficacy and safety of glycopyrrolate/formoterol metered dose inhaler formulated using co-suspension delivery technology in patients with COPDChest2017151234035727916620
   PubMed Web of Science ®Google Scholar
• HananiaNATashkinDPKerwinEMLong-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary diseaseRespir Med201712610511528427541
   PubMed Web of Science ®Google Scholar
• TanWCSealePIpMTrends in COPD mortality and hospitalizations in countries and regions of Asia-PacificRespirology2009141909719144054
   PubMed Web of Science ®Google Scholar
• FangLGaoPBaoHChronic obstructive pulmonary disease in China: a nationwide prevalence studyLancet Respir Med20186642143029650407
   PubMed Web of Science ®Google Scholar
• FukuchiYNishimuraMIchinoseMCOPD in Japan: the Nippon COPD Epidemiology studyRespirology20049445846515612956
   PubMed Web of Science ®Google Scholar
• LandisSHMuellerovaHManninoDMContinuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012–2013Int J Chron Obstruct Pulmon Dis2014959761124944511
   PubMed Web of Science ®Google Scholar
• YasudaSUZhangLHuangSMThe role of ethnicity in variability in response to drugs: focus on clinical pharmacology studiesClin Pharmacol Ther200884341742318615002
   PubMed Web of Science ®Google Scholar
• CelliBRMacneeWATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEur Respir J200423693294615219010
   PubMed Web of Science ®Google Scholar
• MahlerDAWeinbergDHWellsCKFeinsteinARThe measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexesChest19848567517586723384
   PubMed Web of Science ®Google Scholar
• MahlerDAWatermanLAWardJMccuskerCZuwallackRBairdJCValidity and responsiveness of the self-administered comput-erized versions of the baseline and transition dyspnea indexesChest200713241283129017646223
   PubMed Web of Science ®Google Scholar
• MahlerDAWitekTJThe MCID of the transition dyspnea index is a total score of one unitCOPD2005219910317136969
   PubMedGoogle Scholar
• JonesPWSt. George’s Respiratory Questionnaire: MCIDCOPD200521757917136966
   PubMedGoogle Scholar
• DonohueJFMinimal clinically important differences in COPD lung functionCOPD20052111112417136971
   PubMedGoogle Scholar
• MartinezFJFabbriLMFergusonGTBaseline symptom score impact on benefits of glycopyrrolate/formoterol metered dose inhaler in COPDChest201715261169117828720336
   PubMed Web of Science ®Google Scholar
• RabeKMartinezFRodriguez-RoisinRPT003, a novel co-suspension MDI glycopyrronium/formoterol fixed-dose combination is superior to monocomponents in patients with COPDEur Respir J201559supplPA463
   Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
   PubMed Web of Science ®Google Scholar
• CelliBCraterGKilbrideSOnce-daily umeclidinium/ vilanterol 125/25 mcg in COPD: a randomized, controlled studyChest2014145598199124385182
   PubMed Web of Science ®Google Scholar
• D’UrzoADRennardSIKerwinEMEfficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD studyRespir Res20141512325756831
   PubMed Web of Science ®Google Scholar
• DonohueJFMaleki-YazdiMRKilbrideSMehtaRKalbergCChurchAEfficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPDRespir Med2013107101538154623830094
   PubMed Web of Science ®Google Scholar
• SinghDJonesPWBatemanEDEfficacy and safety of acli-dinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised studyBMC Pulm Med20141417825404569
   PubMed Web of Science ®Google Scholar
• BuhlRMaltaisFAbrahamsRTiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)Eur Respir J201545496997925573406
   PubMed Web of Science ®Google Scholar
• DecramerMAnzuetoAKerwinEEfficacy and safety of umecli-dinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trialsLancet Respir Med20142647248624835833
   PubMed Web of Science ®Google Scholar
• MahlerDAKerwinEAyersTFLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (indacaterol/glycopyrrolate) versus its mono-components and placebo in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med201519291068107926177074
   PubMed Web of Science ®Google Scholar
• VehringRLechuga-BallesterosDJoshiVNogaBDwivediSKCosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalersLangmuir20122842150151502322985189
   PubMed Web of Science ®Google Scholar
• DotyASchroederJVangKDrug delivery from an innovative LAMA/LABA co-suspension delivery technology fixed-dose combination MDI: evidence of consistency, robustness, and reliabilityAAPS PharmSciTech201819283784429019170
   PubMed Web of Science ®Google Scholar
• TaylorGWarrenSDwivediSGamma scintigraphic pulmonary deposition study of glycopyrronium/formoterol metered dose inhaler formulated using co-suspension delivery technologyEur J Pharm Sci201811145045729055732
   PubMed Web of Science ®Google Scholar
• Bosnic-AnticevichSChrystynHCostelloRWThe use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomesInt J Chron Obstruct Pulmon Dis201712597128053517
   PubMed Web of Science ®Google Scholar
• PriceDChrystynHKaplanAEffectiveness of same versus mixed asthma inhaler devices: a retrospective observational study in primary careAllergy Asthma Immunol Res20124418419122754711
   PubMed Web of Science ®Google Scholar
• LavoriniFCorriganCJBarnesPJRetail sales of inhalation devices in European countries: so much for a global policyRespir Med201110571099110321489771
   PubMed Web of Science ®Google Scholar
• JonesPWBeehKMChapmanKRDecramerMMahlerDAWedzichaJAMinimal clinically important differences in pharmacological trialsAm J Respir Crit Care Med2014189325025524383418
   PubMed Web of Science ®Google Scholar
• FakihFSpangenthalSSigalBRandomized study of the effects of Aerochamber Plus® Flow-Vu® on the efficacy, pharmacokinetics and safety of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler in patients with chronic obstructive pulmonary diseaseRespir Med2018138748029724397
   PubMed Web of Science ®Google Scholar
• BattistiWPWagerEBaltzerLGood publication practice for communicating company-sponsored medical research: GPP3Ann Intern Med2015163646146426259067
   PubMed Web of Science ®Google Scholar